AU4994000A - Low-dose il-1beta-induced photoreceptor cell rescue without retinal dysplasia - Google Patents

Low-dose il-1beta-induced photoreceptor cell rescue without retinal dysplasia Download PDF

Info

Publication number
AU4994000A
AU4994000A AU49940/00A AU4994000A AU4994000A AU 4994000 A AU4994000 A AU 4994000A AU 49940/00 A AU49940/00 A AU 49940/00A AU 4994000 A AU4994000 A AU 4994000A AU 4994000 A AU4994000 A AU 4994000A
Authority
AU
Australia
Prior art keywords
composition
dystrophic
retinal
retina
neural tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49940/00A
Other languages
English (en)
Inventor
Henry Klassen
Simon J. Whiteley
Michael J. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Original Assignee
Schepens Eye Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Research Institute Inc filed Critical Schepens Eye Research Institute Inc
Publication of AU4994000A publication Critical patent/AU4994000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU49940/00A 1999-05-06 2000-05-08 Low-dose il-1beta-induced photoreceptor cell rescue without retinal dysplasia Abandoned AU4994000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13285599P 1999-05-06 1999-05-06
US60132855 1999-05-06
PCT/US2000/012565 WO2000068267A1 (fr) 1999-05-06 2000-05-08 RECUPERATION DE CELLULES PHOTORECEPTRICES INDUITE PAR IL-1β ADMINISTREE A FAIBLE DOSE ET NE PROVOQUANT PAS DE DYSPLASIE RETINIENNE

Publications (1)

Publication Number Publication Date
AU4994000A true AU4994000A (en) 2000-11-21

Family

ID=22455907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49940/00A Abandoned AU4994000A (en) 1999-05-06 2000-05-08 Low-dose il-1beta-induced photoreceptor cell rescue without retinal dysplasia

Country Status (5)

Country Link
EP (1) EP1179020A4 (fr)
JP (1) JP2003525206A (fr)
AU (1) AU4994000A (fr)
CA (1) CA2372738A1 (fr)
WO (1) WO2000068267A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
AU677951B2 (en) * 1992-02-14 1997-05-15 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors

Also Published As

Publication number Publication date
JP2003525206A (ja) 2003-08-26
CA2372738A1 (fr) 2000-11-16
WO2000068267A9 (fr) 2001-06-14
EP1179020A1 (fr) 2002-02-13
WO2000068267A1 (fr) 2000-11-16
EP1179020A4 (fr) 2004-08-18

Similar Documents

Publication Publication Date Title
DE60021760T2 (de) Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US7282482B2 (en) NGF for the prevention of demyelination in the nervous system
BROD et al. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons
EP0434625B1 (fr) IGF-I pour le traitement des effets secondaires dans le traitement par stéroides
Wilkinson et al. Centrally acting vasopressin contributes to endotoxin tolerance
AU630530B2 (en) Method of treating fibrotic disorders
JP4102437B2 (ja) アクチビンおよびインヒビン刺激因子を含有する医薬組成物
US7951359B2 (en) Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy
EP0610336B1 (fr) Traitement des troubles neurologiques a l'aide d'un compose inhibant l'interleukin-1
Whiteley et al. Photoreceptor rescue after low-dose intravitreal IL-1β Injection in the RCS Rat
DE69626050T2 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
AU4994000A (en) Low-dose il-1beta-induced photoreceptor cell rescue without retinal dysplasia
US6225300B1 (en) TNF receptor and steroid hormone in a combined therapy
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
US8106096B2 (en) Compositions and methods for treatment of optic nerve diseases
DE60019921T2 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
US7012060B1 (en) TNF receptor and steroid hormone in a combined therapy
Mullen et al. Monoclonal antibody to tumor necrosis factor-α attenuates plasma interleukin-6 levels in porcine Gram-negative sepsis
GB2241891A (en) Tumour necrosis factor compositions for treating inflammatory disease
BAUER et al. Immune Mechanisms Affecting the Functioning of the Central Nervous System (CNS)
EP1602378A1 (fr) Méthode d'administration d'une cytokine au système nerveux central et au systéme lymphatique
RU2195314C1 (ru) Способ лечения больных с атопическим дерматитом
Ganea et al. Vasoactive intestinal peptide: an antiinflammatory neuropeptide
BA32 TGF-B (pglml)
ZA200502301B (en) Treatment of allergic conditions by use of il21.